Anti-CTLA4 antibodies
US10618962B2 · kind B2 · utility
0Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 10, 2016 |
| Grant date | Apr 14, 2020 |
| Priority date | — |
| Expiry date | Oct 10, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides antibodies and antigen binding fragments against CTLA4, which can block the binding of CTLA4 to its ligand. The antibodies of disclosure provide agents for treating diseases, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.